IBS Treatment Market Report

IBS Treatment Market - Global Professional Analysis and Forecast to 2026

  • POSTDATE：Mar 08, 2020
  • PAGES：136
  • REPORT CODE：GMM499391
  • REPORT SUMMARY
  • TABLE OF CONTENTS

  • The worldwide IBS Treatment market was valued at XX.0 Million US$ in 2018 and is projected to reach XX.0 Million US$ by 2026, at a CAGR (Compound Annual Growth Rate) of 4.4% during the forecast period.

    This report presents the market size and development trends by detailing the IBS Treatment market revenue, market share and growth rate from 2015-2026, and it gives a thorough analysis by various product types, applications, regions, and main participants. The market conditions (2015-2019), corporate competition pattern, corporate SWOT analysis are elaborated, and other qualitative analyses like market dynamics, market penetration, market business environment analyses, the regional regulatory scenario in the IBS Treatment market will be shown in this report. In short, this report will comprehensively reveal the characteristics of IBS Treatment industry and will help you to build a panoramic view of the industrial development.

    IBS Treatment Market, By Type:

    • By Types

    • IBS-D

    • IBS-C

    • IBS-M

    • By Drugs Type

    • Lubiprostone

    • Linaclotide

    • Eluxadoline

    • Rifaximin

    • Alosetron

    • Others

    IBS Treatment Market, By Application:

    • Hospitals

    • Clinics

    • Research Laboratories

    Some of the leading players are as follows:

    • Ironwood Pharmaceuticals, Inc. (U.S.)

    • Valeant Pharmaceuticals (Canada)

    • Abbott Laboratories (U.S.)

    • Abbott Laboratories (US)

    • Pfizer Inc (U.S.)

    • Allergan Plc (Ireland)

    • Novartis AG (Switzerland)

    • Alfasigma USA, Inc. (Italy)

    • Synthetic Biologics, Inc. (U.S.)

    • Synergy Pharmaceuticals, Inc. (U.S.)

    • Sucampo Pharmaceuticals (US)

    • Ardelyx, Inc. (U.S.)

    • Sucampo Pharmaceuticals (U.S.)

    • RedHill Biopharma Ltd. (Israel)

    • Ipsen (France)

    • AstraZeneca (U.K)

    • Pfizer Inc (US)

    • Protagonist Therapeutics Inc. (U.S.)

    • Innovate Biopharmaceuticals (U.S.)

    • Alfasigma USA, Inc (Italy)

    • Lexicon Pharmaceuticals, Inc. (U.S.)

    • Astellas Pharma Inc. (Japan)

    Geographically, Major regions are analyzed in details are as follows:

    • North America

    • Europe

    • Asia Pacific

    • Latin America

    • Middle East & Africa

  • Table of Contents

    1 Methodology and Scope

    • 1.1 Market Segmentation & Scope

      • 1.1.1 Technology Type

      • 1.1.2 Product

      • 1.1.3 Application

      • 1.1.4 Regional scope

      • 1.1.5 Estimates and forecast timeline

    • 1.2 Research Methodology

    • 1.3 Information Procurement

      • 1.3.1 Purchased database

      • 1.3.2 Internal database

      • 1.3.3 Secondary sources

      • 1.3.4 Primary research

      • 1.3.5 Details of primary research

    • 1.4 Information or Data Analysis

      • 1.4.1 Data analysis models

    • 1.5 Market Formulation & Validation

    • 1.6 Model Details

      • 1.6.1 Commodity flow analysis

      • 1.6.2 Volume price analysis

    • 1.7 List of Secondary Sources

    • 1.8 List of Abbreviations

    2 Executive Summary

    • 2.1 Market Outlook

    • 2.2 Segment Outlook

    3 Market Variables, Trends, & Scope

    • 3.1 Market Lineage Outlook

    • 3.1.1 Parent market outlook

      • 3.1.2 Ancillary market outlook

    • 3.2 Market Segmentation

      • 3.2.1 Analysis

    • 3.3 Market Dynamics

      • 3.3.1 Market driver analysis

      • 3.3.2 Market restraint analysis

      • 3.3.3 Industry opportunities

    • 3.4 Penetration & Growth Prospect Mapping

      • 3.4.1 Penetration & growth prospect mapping analysis

    • 3.5 Business Environment Analysis Tools

      • 3.5.1 Porter's five forces analysis

      • 3.5.2 PESTLE analysis

      • 3.5.3 Major deals & strategic alliances analysis

    4 IBS Treatment Market: Technology Type Analysis

    • 4.1 IBS Treatment Technology Type Market Share Analysis, 2018 & 2026

    • 4.2 IBS Treatment Technology Type Market: Segment Dashboard

    • 4.3 Market Size & Forecasts and Trend Analyses, 2015 to 2026 for the Technology Type Segment

      • 4.3.1 By Types

      • 4.3.2 IBS-D

      • 4.3.3 IBS-C

      • 4.3.4 IBS-M

      • 4.3.5 By Drugs Type

      • 4.3.6 Lubiprostone

      • 4.3.7 Linaclotide

      • 4.3.8 Eluxadoline

      • 4.3.9 Rifaximin

      • 4.3.10 Alosetron

      • 4.3.11 Others

    5 IBS Treatment Market: Product Analysis

    • 5.1 IBS Treatment Product Market Share Analysis, 2018 & 2026

    • 5.2 IBS Treatment Product Market: Segment Dashboard

    • 5.3 Market Size & Forecasts and Trend Analyses, 2015 to 2026 for the Product Segment

    6 IBS Treatment Market: Application Analysis

    • 6.1 IBS Treatment Application Market Share Analysis, 2018 & 2026

    • 6.2 IBS Treatment Application Market: Segment Dashboard

    • 6.3 Market Size & Forecasts and Trend Analyses, 2015 to 2026 for the Application Segment

      • 6.3.1 Hospitals

      • 6.3.2 Clinics

      • 6.3.3 Research Laboratories

    7 IBS Treatment Market: Regional Analysis

    • 7.1 IBS Treatment Regional Market Share Analysis, 2018 & 2026

    • 7.2 IBS Treatment Regional Market: Segment Dashboard

    • 7.3 Regional Market Snapshot (Market Size, CAGR, Top Countries)

    • 7.4 List of Players at Regional Level

      • 7.4.1 North America

      • 7.4.2 Europe

      • 7.4.3 Asia Pacific

    • 7.5 SWOT Analysis, by Factor (Political & Legal, Economic and Technological)

      • 7.5.1 North America

      • 7.5.2 Europe

      • 7.5.3 Asia Pacific

      • 7.5.4 Latin America

      • 7.5.5 MEA

    • 7.6 Market Size & Forecasts, and Trend Analysis, 2015 to 2026

      • 7.6.1 North America

      • 7.6.2 Europe

      • 7.6.3 Asia Pacific

      • 7.6.4 Latin America

      • 7.6.5 Middle East & Africa

    8 Competitive Analysis

    • 8.1 Recent Developments & Impact Analysis, by Key Market Participants

    • 8.2 Strategic Framework/Competition Categorization (Key innovators, Market leaders, Emerging players)

    • 8.3 Vendor Landscape

      • 8.3.1 Company market position analysis (Geographic presence, service portfolio, strategic initiatives)

    9 Company Profiles

    • 9.1 Ironwood Pharmaceuticals, Inc. (U.S.)

      • 9.1.1 Ironwood Pharmaceuticals, Inc. (U.S.) Company overview

      • 9.1.2 Financial performance

      • 9.1.3 Product benchmarking

      • 9.1.4 Strategic initiatives

      • 9.1.5 SWOT analysis

    • 9.2 Valeant Pharmaceuticals (Canada)

      • 9.2.1 Valeant Pharmaceuticals (Canada) Company overview

      • 9.2.2 Financial performance

      • 9.2.3 Product benchmarking

      • 9.2.4 Strategic initiatives

      • 9.2.5 SWOT analysis

    • 9.3 Abbott Laboratories (U.S.)

      • 9.3.1 Abbott Laboratories (U.S.) Company overview

      • 9.3.2 Financial performance

      • 9.3.3 Product benchmarking

      • 9.3.4 Strategic initiatives

      • 9.3.5 SWOT analysis

    • 9.4 Abbott Laboratories (US)

      • 9.4.1 Abbott Laboratories (US) Company overview

      • 9.4.2 Financial performance

      • 9.4.3 Product benchmarking

      • 9.4.4 Strategic initiatives

      • 9.4.5 SWOT analysis

    • 9.5 Pfizer Inc (U.S.)

      • 9.5.1 Pfizer Inc (U.S.) Company overview

      • 9.5.2 Financial performance

      • 9.5.3 Product benchmarking

      • 9.5.4 Strategic initiatives

      • 9.5.5 SWOT analysis

    • 9.6 Allergan Plc (Ireland)

      • 9.6.1 Allergan Plc (Ireland) Company overview

      • 9.6.2 Financial performance

      • 9.6.3 Product benchmarking

      • 9.6.4 Strategic initiatives

      • 9.6.5 SWOT analysis

    • 9.7 Novartis AG (Switzerland)

      • 9.7.1 Novartis AG (Switzerland) Company overview

      • 9.7.2 Financial performance

      • 9.7.3 Product benchmarking

      • 9.7.4 Strategic initiatives

      • 9.7.5 SWOT analysis

    • 9.8 Alfasigma USA, Inc. (Italy)

      • 9.8.1 Alfasigma USA, Inc. (Italy) Company overview

      • 9.8.2 Financial performance

      • 9.8.3 Product benchmarking

      • 9.8.4 Strategic initiatives

      • 9.8.5 SWOT analysis

    • 9.9 Synthetic Biologics, Inc. (U.S.)

      • 9.9.1 Synthetic Biologics, Inc. (U.S.) Company overview

      • 9.9.2 Financial performance

      • 9.9.3 Product benchmarking

      • 9.9.4 Strategic initiatives

      • 9.9.5 SWOT analysis

    • 9.10 Synergy Pharmaceuticals, Inc. (U.S.)

      • 9.10.1 Synergy Pharmaceuticals, Inc. (U.S.) Company overview

      • 9.10.2 Financial performance

      • 9.10.3 Product benchmarking

      • 9.10.4 Strategic initiatives

      • 9.10.5 SWOT analysis

    • 9.11 Sucampo Pharmaceuticals (US)

      • 9.11.1 Sucampo Pharmaceuticals (US) Company overview

      • 9.11.2 Financial performance

      • 9.11.3 Product benchmarking

      • 9.11.4 Strategic initiatives

      • 9.11.5 SWOT analysis

    • 9.12 Ardelyx, Inc. (U.S.)

      • 9.12.1 Ardelyx, Inc. (U.S.) Company overview

      • 9.12.2 Financial performance

      • 9.12.3 Product benchmarking

      • 9.12.4 Strategic initiatives

      • 9.12.5 SWOT analysis

    • 9.13 Sucampo Pharmaceuticals (U.S.)

      • 9.13.1 Sucampo Pharmaceuticals (U.S.) Company overview

      • 9.13.2 Financial performance

      • 9.13.3 Product benchmarking

      • 9.13.4 Strategic initiatives

      • 9.13.5 SWOT analysis

    • 9.14 RedHill Biopharma Ltd. (Israel)

      • 9.14.1 RedHill Biopharma Ltd. (Israel) Company overview

      • 9.14.2 Financial performance

      • 9.14.3 Product benchmarking

      • 9.14.4 Strategic initiatives

      • 9.14.5 SWOT analysis

    • 9.15 Ipsen (France)

      • 9.15.1 Ipsen (France) Company overview

      • 9.15.2 Financial performance

      • 9.15.3 Product benchmarking

      • 9.15.4 Strategic initiatives

      • 9.15.5 SWOT analysis

    • 9.16 AstraZeneca (U.K)

      • 9.16.1 AstraZeneca (U.K) Company overview

      • 9.16.2 Financial performance

      • 9.16.3 Product benchmarking

      • 9.16.4 Strategic initiatives

      • 9.16.5 SWOT analysis

    • 9.17 Pfizer Inc (US)

      • 9.17.1 Pfizer Inc (US) Company overview

      • 9.17.2 Financial performance

      • 9.17.3 Product benchmarking

      • 9.17.4 Strategic initiatives

      • 9.17.5 SWOT analysis

    • 9.18 Protagonist Therapeutics Inc. (U.S.)

      • 9.18.1 Protagonist Therapeutics Inc. (U.S.) Company overview

      • 9.18.2 Financial performance

      • 9.18.3 Product benchmarking

      • 9.18.4 Strategic initiatives

      • 9.18.5 SWOT analysis

    • 9.19 Innovate Biopharmaceuticals (U.S.)

      • 9.19.1 Innovate Biopharmaceuticals (U.S.) Company overview

      • 9.19.2 Financial performance

      • 9.19.3 Product benchmarking

      • 9.19.4 Strategic initiatives

      • 9.19.5 SWOT analysis

    • 9.20 Alfasigma USA, Inc (Italy)

      • 9.20.1 Alfasigma USA, Inc (Italy) Company overview

      • 9.20.2 Financial performance

      • 9.20.3 Product benchmarking

      • 9.20.4 Strategic initiatives

      • 9.20.5 SWOT analysis

    • 9.21 Lexicon Pharmaceuticals, Inc. (U.S.)

      • 9.21.1 Lexicon Pharmaceuticals, Inc. (U.S.) Company overview

      • 9.21.2 Financial performance

      • 9.21.3 Product benchmarking

      • 9.21.4 Strategic initiatives

      • 9.21.5 SWOT analysis

    • 9.22 Astellas Pharma Inc. (Japan)

      • 9.22.1 Astellas Pharma Inc. (Japan) Company overview

      • 9.22.2 Financial performance

      • 9.22.3 Product benchmarking

      • 9.22.4 Strategic initiatives

      • 9.22.5 SWOT analysis

     

    The List of Tables and Figures (Totals 81 Figures and 165 Tables)

    • Figure By Types IBS Treatment market, 2015 - 2026 (USD Million)

    • Figure IBS-D IBS Treatment market, 2015 - 2026 (USD Million)

    • Figure IBS-C IBS Treatment market, 2015 - 2026 (USD Million)

    • Figure IBS-M IBS Treatment market, 2015 - 2026 (USD Million)

    • Figure By Drugs Type IBS Treatment market, 2015 - 2026 (USD Million)

    • Figure Lubiprostone IBS Treatment market, 2015 - 2026 (USD Million)

    • Figure Linaclotide IBS Treatment market, 2015 - 2026 (USD Million)

    • Figure Eluxadoline IBS Treatment market, 2015 - 2026 (USD Million)

    • Figure Rifaximin IBS Treatment market, 2015 - 2026 (USD Million)

    • Figure Alosetron IBS Treatment market, 2015 - 2026 (USD Million)

    • Figure Others IBS Treatment market, 2015 - 2026 (USD Million)

    • Figure Hospitals market, 2015 - 2026 (USD Million)

    • Figure Clinics market, 2015 - 2026 (USD Million)

    • Figure Research Laboratories market, 2015 - 2026 (USD Million)

    • Table List of players in North America

    • Table List of players in Europe

    • Table List of players in Asia Pacific

    • Table SWOT analysis

    • Table North America IBS Treatment market, by country, 2015 - 2026 (USD Million)

    • Table North America IBS Treatment market, by type, 2015 - 2026 (USD Million)

    • Table North America IBS Treatment market, by product, 2015 - 2026 (USD Million)

    • Table North America IBS Treatment market, by application, 2015 - 2026 (USD Million)

    • Table Regulatory scenario

    • Table U.S. IBS Treatment market, by type, 2015 - 2026 (USD Million)

    • Table U.S. IBS Treatment market, by product, 2015 - 2026 (USD Million)

    • Table U.S. IBS Treatment market, by application, 2015 - 2026 (USD Million)

    • Table Regulatory scenario

    • Table Canada IBS Treatment market, by type, 2015 - 2026 (USD Million)

    • Table Canada IBS Treatment market, by product, 2015 - 2026 (USD Million)

    • Table Canada IBS Treatment market, by application, 2015 - 2026 (USD Million)

    • Table Europe IBS Treatment market, by country, 2015 - 2026 (USD Million)

    • Table Europe IBS Treatment market, by type, 2015 - 2026 (USD Million)

    • Table Europe IBS Treatment market, by product, 2015 - 2026 (USD Million)

    • Table Europe IBS Treatment market, by application, 2015 - 2026 (USD Million)

    • Table Regulatory scenario

    • Table U.K. IBS Treatment market, by type, 2015 - 2026 (USD Million)

    • Table U.K. IBS Treatment market, by product, 2015 - 2026 (USD Million)

    • Table U.K. IBS Treatment market, by application, 2015 - 2026 (USD Million)

    • Table Regulatory scenario

    • Table Germany IBS Treatment market, by type, 2015 - 2026 (USD Million)

    • Table Germany IBS Treatment market, by product, 2015 - 2026 (USD Million)

    • Table Germany IBS Treatment market, by application, 2015 - 2026 (USD Million)

    • Table Regulatory scenario

    • Table France IBS Treatment market, by type, 2015 - 2026 (USD Million)

    • Table France IBS Treatment market, by product, 2015 - 2026 (USD Million)

    • Table France IBS Treatment market, by application, 2015 - 2026 (USD Million)

    • Table Regulatory scenario

    • Table Italy IBS Treatment market, by type, 2015 - 2026 (USD Million)

    • Table Italy IBS Treatment market, by product, 2015 - 2026 (USD Million)

    • Table Italy IBS Treatment market, by application, 2015 - 2026 (USD Million)

    • Table Regulatory scenario

    • Table Spain IBS Treatment market, by type, 2015 - 2026 (USD Million)

    • Table Spain IBS Treatment market, by product, 2015 - 2026 (USD Million)

    • Table Spain IBS Treatment market, by application, 2015 - 2026 (USD Million)

    • Table Asia Pacific IBS Treatment market, by country, 2015 - 2026 (USD Million)

    • Table Asia Pacific IBS Treatment market, by type, 2015 - 2026 (USD Million)

    • Table Asia Pacific IBS Treatment market, by product, 2015 - 2026 (USD Million)

    • Table Asia Pacific IBS Treatment market, by application, 2015 - 2026 (USD Million)

    • Table Regulatory scenario

    • Table China IBS Treatment market, by type, 2015 - 2026 (USD Million)

    • Table China IBS Treatment market, by product, 2015 - 2026 (USD Million)

    • Table China IBS Treatment market, by application, 2015 - 2026 (USD Million)

    • Table Regulatory scenario

    • Table Japan IBS Treatment market, by type, 2015 - 2026 (USD Million)

    • Table Japan IBS Treatment market, by product, 2015 - 2026 (USD Million)

    • Table Japan IBS Treatment market, by application, 2015 - 2026 (USD Million)

    • Table Regulatory scenario

    • Table India IBS Treatment market, by type, 2015 - 2026 (USD Million)

    • Table India IBS Treatment market, by product, 2015 - 2026 (USD Million)

    • Table India IBS Treatment market, by application, 2015 - 2026 (USD Million)

    • Table Latin America IBS Treatment market, by country, 2015 - 2026 (USD Million)

    • Table Latin America IBS Treatment market, by type, 2015 - 2026 (USD Million)

    • Table Latin America IBS Treatment market, by product, 2015 - 2026 (USD Million)

    • Table Latin America IBS Treatment market, by application, 2015 - 2026 (USD Million)

    • Table Regulatory scenario

    • Table Brazil IBS Treatment market, by type, 2015 - 2026 (USD Million)

    • Table Brazil IBS Treatment market, by product, 2015 - 2026 (USD Million)

    • Table Brazil IBS Treatment market, by application, 2015 - 2026 (USD Million)

    • Table Regulatory scenario

    • Table Mexico IBS Treatment market, by type, 2015 - 2026 (USD Million)

    • Table Mexico IBS Treatment market, by product, 2015 - 2026 (USD Million)

    • Table Mexico IBS Treatment market, by application, 2015 - 2026 (USD Million)

    • Table Regulatory scenario

    • Table Argentina IBS Treatment market, by type, 2015 - 2026 (USD Million)

    • Table Argentina IBS Treatment market, by product, 2015 - 2026 (USD Million)

    • Table Argentina IBS Treatment market, by application, 2015 - 2026 (USD Million)

    • Table MEA IBS Treatment market, by country, 2015 - 2026 (USD Million)

    • Table MEA IBS Treatment market, by type, 2015 - 2026 (USD Million)

    • Table MEA IBS Treatment market, by product, 2015 - 2026 (USD Million)

    • Table MEA IBS Treatment market, by application, 2015 - 2026 (USD Million)

    • Table Regulatory scenario

    • Table South Africa IBS Treatment market, by type, 2015 - 2026 (USD Million)

    • Table South Africa IBS Treatment market, by product, 2015 - 2026 (USD Million)

    • Table South Africa IBS Treatment market, by application, 2015 - 2026 (USD Million)

    • Table Regulatory scenario

    • Table Nigeria IBS Treatment market, by type, 2015 - 2026 (USD Million)

    • Table Nigeria IBS Treatment market, by product, 2015 - 2026 (USD Million)

    • Table Nigeria IBS Treatment market, by application, 2015 - 2026 (USD Million)

    • Table Recent Developments & Impact Analysis, by Key Market Participants

    • Table Recent Developments & Impact Analysis, by Key Market Participants

    • Table Company market position analysis

    • Table Company Profiles

    • Table Ironwood Pharmaceuticals, Inc. (U.S.) Production, Value, Price, Gross Margin 2014-2019

    • Table Product benchmarking

    • Table Strategic initiatives

    • Table SWOT analysis

    • Table Company Profiles

    • Table Valeant Pharmaceuticals (Canada) Production, Value, Price, Gross Margin 2014-2019

    • Table Product benchmarking

    • Table Strategic initiatives

    • Table SWOT analysis

    • Table Company Profiles

    • Table Abbott Laboratories (U.S.) Production, Value, Price, Gross Margin 2014-2019

    • Table Product benchmarking

    • Table Strategic initiatives

    • Table SWOT analysis

    • Table Company Profiles

    • Table Abbott Laboratories (US) Production, Value, Price, Gross Margin 2014-2019

    • Table Product benchmarking

    • Table Strategic initiatives

    • Table SWOT analysis

    • Table Company Profiles

    • Table Pfizer Inc (U.S.) Production, Value, Price, Gross Margin 2014-2019

    • Table Product benchmarking

    • Table Strategic initiatives

    • Table SWOT analysis

    • Table Company Profiles

    • Table Allergan Plc (Ireland) Production, Value, Price, Gross Margin 2014-2019

    • Table Product benchmarking

    • Table Strategic initiatives

    • Table SWOT analysis

    • Table Company Profiles

    • Table Novartis AG (Switzerland) Production, Value, Price, Gross Margin 2014-2019

    • Table Product benchmarking

    • Table Strategic initiatives

    • Table SWOT analysis

    • Table Company Profiles

    • Table Alfasigma USA, Inc. (Italy) Production, Value, Price, Gross Margin 2014-2019

    • Table Product benchmarking

    • Table Strategic initiatives

    • Table SWOT analysis

    • Table Company Profiles

    • Table Synthetic Biologics, Inc. (U.S.) Production, Value, Price, Gross Margin 2014-2019

    • Table Product benchmarking

    • Table Strategic initiatives

    • Table SWOT analysis

    • Table Company Profiles

    • Table Synergy Pharmaceuticals, Inc. (U.S.) Production, Value, Price, Gross Margin 2014-2019

    • Table Product benchmarking

    • Table Strategic initiatives

    • Table SWOT analysis

    • Table Company Profiles

    • Table Sucampo Pharmaceuticals (US) Production, Value, Price, Gross Margin 2014-2019

    • Table Product benchmarking

    • Table Strategic initiatives

    • Table SWOT analysis

    • Table Company Profiles

    • Table Ardelyx, Inc. (U.S.) Production, Value, Price, Gross Margin 2014-2019

    • Table Product benchmarking

    • Table Strategic initiatives

    • Table SWOT analysis

    • Table Company Profiles

    • Table Sucampo Pharmaceuticals (U.S.) Production, Value, Price, Gross Margin 2014-2019

    • Table Product benchmarking

    • Table Strategic initiatives

    • Table SWOT analysis

    • Table Company Profiles

    • Table RedHill Biopharma Ltd. (Israel) Production, Value, Price, Gross Margin 2014-2019

    • Table Product benchmarking

    • Table Strategic initiatives

    • Table SWOT analysis

    • Table Company Profiles

    • Table Ipsen (France) Production, Value, Price, Gross Margin 2014-2019

    • Table Product benchmarking

    • Table Strategic initiatives

    • Table SWOT analysis

    • Table Company Profiles

    • Table AstraZeneca (U.K) Production, Value, Price, Gross Margin 2014-2019

    • Table Product benchmarking

    • Table Strategic initiatives

    • Table SWOT analysis

    • Table Company Profiles

    • Table Pfizer Inc (US) Production, Value, Price, Gross Margin 2014-2019

    • Table Product benchmarking

    • Table Strategic initiatives

    • Table SWOT analysis

    • Table Company Profiles

    • Table Protagonist Therapeutics Inc. (U.S.) Production, Value, Price, Gross Margin 2014-2019

    • Table Product benchmarking

    • Table Strategic initiatives

    • Table SWOT analysis

    • Table Company Profiles

    • Table Innovate Biopharmaceuticals (U.S.) Production, Value, Price, Gross Margin 2014-2019

    • Table Product benchmarking

    • Table Strategic initiatives

    • Table SWOT analysis

    • Table Company Profiles

    • Table Alfasigma USA, Inc (Italy) Production, Value, Price, Gross Margin 2014-2019

    • Table Product benchmarking

    • Table Strategic initiatives

    • Table SWOT analysis

    • Table Company Profiles

    • Table Lexicon Pharmaceuticals, Inc. (U.S.) Production, Value, Price, Gross Margin 2014-2019

    • Table Product benchmarking

    • Table Strategic initiatives

    • Table SWOT analysis

    • Table Company Profiles

    • Table Astellas Pharma Inc. (Japan) Production, Value, Price, Gross Margin 2014-2019

    • Table Product benchmarking

    • Table Strategic initiatives

    • Table SWOT analysis

Report Version Choose

Report

BUY NOW

Our Customers

Beyond grateful for the confidence and support from all partners and customers.A win-win situation is our ultimate pursuit.

Beyond Consulting, Future is Feasible

We provide more professional and intelligent market reports to complement your business decisions.

CONTACT US